Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22807046 | 1.00 | HDAC4 (0.50) | HDAC4HDAC7HDAC5KDM4ECES2 | |
| Hydrochloric Acid SCHEMBL5967048 | 0.98 | HDAC4 (0.49) | HDAC4HDAC7HDAC5KDM4ECES2 | |
| Hydrochloric Acid SCHEMBL7368960 | 0.93 | HDAC4 (0.44) | HDAC4HDAC7HDAC5KDM4ECES2 | |
| SCHEMBL2597793 | 0.89 | HDAC4 (0.46) | HDAC4HDAC7HDAC5KDM4ECES2 | |
| SCHEMBL3895480 | 0.88 | KMT2A (0.52) | KMT2AALDH1A1LMNA | |
| SCHEMBL22807068 | 0.84 | LMNA (0.45) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL30646488 | 0.84 | LMNA (0.45) | HDAC4HDAC7HDAC5CES2CES1 | |
| SCHEMBL28471244 | 0.83 | HDAC4 (0.53) | HDAC4HDAC7HDAC5KDM4ECES2 | |
| Hydrochloric Acid SCHEMBL22807481 | 0.83 | LMNA (0.44) | HDAC4HDAC7HDAC5CES2CES1 | |
| Hydrochloric Acid SCHEMBL29598699 | 0.83 | LMNA (0.44) | HDAC4HDAC7HDAC5CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4543436-A1 | FUSED BICYCLIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-114206342-B | Allosteric EGFR inhibitors and methods of use thereof | 达纳-法伯癌症研究所股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2023250321-A1 | FUSED BICYCLIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20220233545-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2022-07-28 | — | — | US | disclosed |
| EP-3986407-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114206342-A | Allosteric EGFR inhibitors and methods of use thereof | 达纳-法伯癌症研究所股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB3, ERBB2 | HDAC4 1701/4885HDAC7 1803/4885HDAC5 2748/4885 |
| US-20220233545-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HDAC4 4440/4885HDAC7 3852/4885HDAC5 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.